Randomized phase III Study of 5‐fluorouracil plus high dose folinic acid versus 5‐fluorouracil plus folinic acid plus methyl‐lomustine for patients with advanced colorectal cancer

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Cancer

• Publication date

  1995-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(19951115)76:10<1709::AID-CNCR2820761006>3.0.CO;2-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A Southwest Oncology Group study

  1993cited by this paper
• Cancer statistics, 1991

  1991cited by this paper
• Comprehensive criteria for assessing therapy-induced toxicity.

  1990cited by this paper
• Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.

  1989cited by this paper
• Prolongation of the disease-free interval in surgically treated rectal carcinoma.

  1985cited by this paper
• Metastatic colorectal carcinoma: A prospective randomized trial of Methyl‐CCNU, 5‐fluorouracil (5‐FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF‐strep)

  1983cited by this paper
• Combination chemotherapy of advanced colorectal cancer utilizing 5‐fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: A phase III trial by the eastern cooperative oncology group (EST: 4275)

  1982cited by this paper
• Chapter 23 – CLINICAL USE OF NITROSOUREAS IN GASTROINTESTINAL CANCER

  1981cited by this paper
• 5 FU infusion with mitomycin‐C vs. 5 FU infusion with methyl‐CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study

  1979cited by this paper
• A randomized study of two different schedules of methyl CCNU, 5‐FU and vincristine for metastatic colorectal carcinoma

  1979cited by this paper
• Phase ii evaluation of ftorafur in previously untreated colorectal cancer: A southwest oncology group study

  1979cited by this paper
• Randomized trial of melphalan plus 5-fluorouracil (5-FU) versus methyl-CCNU plus 5-FU in patients with advanced colorectal cancer.

  1978cited by this paper
• Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5‐fluorouracil, alone or in combination with cyclophosphamide or 6‐thioguanine, with intravenous 5‐fluorouracil or beta‐2′‐deoxythioguanosine or with oral 3(4‐methyl‐cyclohexyl)‐1(2‐chlorethyl)‐1‐nitrosourea. A phase II‐III stu

  1978cited by this paper
• Lack of effectiveness of combined 5‐fluorouracil and methyl‐ccnu therapy in advanced colorectal cancer

  1977cited by this paper
• Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.

  1977cited by this paper
• Fluorouracil, methyl‐ccnu and vincristine in cancer of the colon

  1976cited by this paper
• 5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.

  1976cited by this paper
• Therapy for gastrointestinal cancer with the nitrosoureas alone and in drug combination.

  1976cited by this paper
• Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.

  1976cited by this paper
• Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.

  1976cited by this paper
• Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine.

  1975cited by this paper
• Clinical management of advanced gastrointestinal cancer

  1975cited by this paper
• Brief Communication: Therapy of Advanced Colorectal Cancer With a Combination of 5-Flourouracil, Methyl-l,3-cis(2-chlorethyl)-1-nitrosourea, and Vincristine

  1975cited by this paper
• Therapy of advanced gastrointestinal cancer with the nitrosoureas.

  1973cited by this paper
• Historical development and future promise of the nitrosoureas as anticancer agents.

  1973cited by this paper
• Historical development and future promise of the nitrosoureas as anticancer agents.

  1973cited by this paper
• Therapy of advanced gastrointestinal cancer with the nitrosoureas.

  1973cited by this paper
• Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy.

  1972cited by this paper

• Ursolic acid benzaldehyde chalcone, leads to inhibition of cell proliferation and arrests cycle in G1/G0 phase in colon cancer

  2017cites this paper
• Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters

  2016cites this paper
• Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells

  2016cites this paper
• Sensitization of 5-Fluorouracil-Resistant SNUC5 Colon Cancer Cells to Apoptosis by α-Mangostin

  2016cites this paper
• tRNA Modifying Enzymes, NSUN2 and METTL1, Determine Sensitivity to 5-Fluorouracil in HeLa Cells

  2014cites this paper
• PAK1-dependent MAPK pathway activation is required for colorectal cancer cell proliferation

  2012cites this paper
• ANALIZA UČESTALOSTI I TIPOVA MUTACIJA KRAS I BRAF GENA U KARCINOMIMA KOLOREKTUMA U POPULACIJI SRBIJE

  2012cites this paper
• Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment.

  2011cites this paper
• CD24‐dependent MAPK pathway activation is required for colorectal cancer cell proliferation

  2010cites this paper
• Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells.

  2009cites this paper
• Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft.

  2007cites this paper
• Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis

  2005cites this paper
• A systematic overview of chemotherapy effects in colorectal cancer.

  2001cites this paper
• Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.

  1997cites this paper